MX2021012871A - Generacion de polipeptidos derivados de anticuerpos mediante intercambio de cadenas polipeptidicas. - Google Patents

Generacion de polipeptidos derivados de anticuerpos mediante intercambio de cadenas polipeptidicas.

Info

Publication number
MX2021012871A
MX2021012871A MX2021012871A MX2021012871A MX2021012871A MX 2021012871 A MX2021012871 A MX 2021012871A MX 2021012871 A MX2021012871 A MX 2021012871A MX 2021012871 A MX2021012871 A MX 2021012871A MX 2021012871 A MX2021012871 A MX 2021012871A
Authority
MX
Mexico
Prior art keywords
polypeptide chain
antibody
generation
chain exchange
derived polypeptides
Prior art date
Application number
MX2021012871A
Other languages
English (en)
Inventor
Guy Georges
Ulrich Brinkmann
Eike Hoffmann
Stefan Dengl
Sabine Imhof-Jung
Steffen Dickopf
Can Martin Buldun
David Zilian
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2021012871A publication Critical patent/MX2021012871A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un conjunto de polipéptidos heterodiméricos y sus usos, por ejemplo, para generar aglutinantes de antígenos multiespecíficos mediante el intercambio de cadenas polipeptídicas.
MX2021012871A 2019-04-25 2020-04-24 Generacion de polipeptidos derivados de anticuerpos mediante intercambio de cadenas polipeptidicas. MX2021012871A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19171068 2019-04-25
PCT/EP2020/061412 WO2020216878A1 (en) 2019-04-25 2020-04-24 Generation of antibody-derived polypeptides by polypeptide chain exchange

Publications (1)

Publication Number Publication Date
MX2021012871A true MX2021012871A (es) 2021-11-17

Family

ID=66334197

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012871A MX2021012871A (es) 2019-04-25 2020-04-24 Generacion de polipeptidos derivados de anticuerpos mediante intercambio de cadenas polipeptidicas.

Country Status (12)

Country Link
US (1) US20220033525A1 (es)
EP (1) EP3959244A1 (es)
JP (1) JP2022531128A (es)
KR (1) KR20220005031A (es)
CN (1) CN113728002A (es)
AU (1) AU2020261250A1 (es)
BR (1) BR112021020843A2 (es)
CA (1) CA3132275A1 (es)
IL (1) IL287400A (es)
MX (1) MX2021012871A (es)
TW (1) TW202106714A (es)
WO (1) WO2020216878A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1010297A2 (pt) 2009-04-07 2017-06-06 Roche Glycart Ag anticorpos biespecíficos trivalentes.
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2022125986A1 (en) * 2020-12-10 2022-06-16 Invenra Inc. Orthogonal mutations for heterodimerization
CA3227537A1 (en) 2021-07-27 2023-02-02 Morphosys Ag Combinations of antigen binding molecules

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
NZ517906A (en) 1999-10-04 2003-01-31 Medicago Inc Cloning of genomic sequences encoding nitrite reductase (NiR) for use in regulated expression of foreign genes in host plants
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CN102958942A (zh) 2009-12-29 2013-03-06 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
RU2604490C2 (ru) 2010-11-05 2016-12-10 Займворкс Инк. ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
SI2766397T1 (sl) * 2011-10-11 2018-09-28 F. Hoffmann-La Roche Ag Izboljšano sestavljanje bispecifičnih protiteles
LT2794905T (lt) 2011-12-20 2020-07-10 Medimmune, Llc Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams
PT2838918T (pt) 2012-04-20 2019-08-23 Merus Nv Métodos e meios para a produção de moléculas heterrodiméricas do tipo ig
CN104955953B (zh) * 2012-11-27 2019-04-26 亚洲大学校产学协力团 高效诱导抗体重链恒定区的异源二聚体形成的ch3域变体对，其制备方法及用途
EP3227332B1 (en) * 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
CN106883297B (zh) * 2015-12-16 2019-12-13 苏州康宁杰瑞生物科技有限公司 基于ch3结构域的异二聚体分子、其制备方法及用途
RU2745648C2 (ru) * 2016-07-19 2021-03-30 Ибентрус, Инк. Биспецифические белки и способы их получения
MX2020003497A (es) * 2017-10-20 2020-07-22 Hoffmann La Roche Metodo para generar anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
BR112020007736A2 (pt) * 2017-10-30 2020-10-20 F. Hoffmann-La Roche Ag composição e método de tratamento
KR20200079492A (ko) * 2017-11-01 2020-07-03 에프. 호프만-라 로슈 아게 이중특이성 2+1 컨터체

Also Published As

Publication number Publication date
CA3132275A1 (en) 2020-10-29
EP3959244A1 (en) 2022-03-02
WO2020216878A1 (en) 2020-10-29
IL287400A (en) 2021-12-01
US20220033525A1 (en) 2022-02-03
KR20220005031A (ko) 2022-01-12
BR112021020843A2 (pt) 2022-02-01
CN113728002A (zh) 2021-11-30
TW202106714A (zh) 2021-02-16
JP2022531128A (ja) 2022-07-06
AU2020261250A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
MX2021012871A (es) Generacion de polipeptidos derivados de anticuerpos mediante intercambio de cadenas polipeptidicas.
PH12019550147A1 (en) Engineered transferrin receptor binding polypeptides
MX2018015592A (es) Anticuerpos inhibidores de puntos de control biespecificos.
CR20200563A (es) Agentes aglutinantes de psma y usos de estos
MX2019002946A (es) Anticuerpos anti-pd-1 y sus usos.
MY198059A (en) Anti-ox40 antibodies and their uses
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
MX2019011778A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
EA201692568A1 (ru) Составы с полипептидами-рецепторами и связанные с ними способы
MX2021000459A (es) Metodo para producir celulas t gamma y delta.
MX2021003654A (es) Metodo para seleccionar neoepitopes.
MX2019011758A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
MX2022000893A (es) Metodo de obtencion de mitocondrias de celulas y mitocondrias obtenidas.
MX2021010783A (es) Formulaciones de anticuerpo anti-il-36r.
PH12020551948A1 (en) Monospecific and multispecific anti-tmeff2 antibodies and their uses
MX2019008241A (es) Un enlazador polipeptídico para preparar anticuerpos multispecíficos.
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
MX2019001465A (es) Metodo de produccion de cetoenoles ciclicos sustituidos con espirocetales.
MX2021007119A (es) Metodos para producir anticuerpos heterodimericos.
MX2021000797A (es) Anticuerpos agonistas de cd226.
PH12019502075A1 (en) A liquid formulation of anti-tnf alpha antibody
CR20220228A (es) Anticuerpos trem2 y usos de estos
MX2021015301A (es) Métodos de cultivo celular y composiciones para la producción de anticuerpos.
CR20220061A (es) Anticuerpos que se unen a células cancerosas y que dirigen radionucleidos a dichas células
MX2021007141A (es) Sintesis de gamma-carbolinas fusionadas con heterociclo sustituido.